Abstract 17P
Background
Early CD8+ T cell responses to PD-1 blockade are well-characterised. However, an understanding of the long-term clonal and transcriptomic signatures of complete response (CR) to Immune Checkpoint Blockade (ICB) is currently lacking. We aimed to identify and describe CD8+ T cell clonal and transcriptomic changes post complete response to PD-1 blockade in metastatic melanoma (MM).
Methods
We performed single-cell RNA sequencing (scRNAseq) of both the T cell receptor (TCR) and transcriptomes of PBMCs and sorted peripheral CD8+ T cells in patients with MM with a complete response to PD-1 blockade (n=10), patients with progressive disease (PD, n=6) and healthy donors (HD, n=2). Blood was sampled at multiple time points, including a median of 3.2 years following cessation of PD-1 blockade for CR.
Results
Following a CR and cessation of ICB, there is increased abundance of a subtype of CD8+ T cell characterised by high expression of NK-associated genes, termed a killer-like subset. Using the top 25 genes upregulated by this subset to generate a ‘Killer Score’, we show that patients with CR to anti-PD-1 demonstrate a broad increase in killer gene expression over time absent in those with PD and HDs. By tracking key clones through TCR usage, we identify those which are stable/expanding from pre-treatment to post treatment, occupy >0.5% of the repertoire and are persistent post-cessation of ICB, terming these large expanding persistent clones. These clones have a predominantly cytotoxic, effector, gene expression profile and display surface markers consistent with a recently-described ‘Long-lived Effector Cell’ subtype.
Conclusions
CR to PD-1 blockade is associated with persistence of highly-cytotoxic effector CD8+ T cells that circulate years after cessation of treatment. Whilst similar subsets have been implicated with chronic viral infection, these observations are novel in the cancer setting and have important implications for mechanisms of durable disease control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Wellcome Trust, Cancer Research UK, National Institute for Health Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Cold atmospheric plasma-activated fluids as a potential new intravesical agent for the treatment of bladder cancer
Presenter: Maria Filomena Botelho
Session: Poster session 09
90P - Discovery of CMPD1 as a tumor-specific cytotoxic microtubule inhibitor
Presenter: Mamoru Takada
Session: Poster session 09
91P - Erythroid precursor-differentiated myeloid cells promote pulmonary metastasis in hepatocellular carcinoma
Presenter: Wei-hang Zhu
Session: Poster session 09
92P - Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs
Presenter: Hsing-Pang Hsieh
Session: Poster session 09
93P - Transcriptome changes of immune cells across chemotherapy of triple-negative breast cancer
Presenter: Tatiana Gerashchenko
Session: Poster session 09
509P - Spatial analysis of tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Presenter: Markus Kleinberger
Session: Poster session 09
510P - CD47 regulates cellular and metabolic plasticity in glioblastoma
Presenter: Ruhi Polara
Session: Poster session 09
511P - Immunodisruptive conditions and glioma diagnosis: 24-year retrospective study of an under-recognized scenario
Presenter: Santiago Cabezas-Camarero
Session: Poster session 09
512P - Heterozygous germline Fanconi anemia-related gene mutations increase susceptibility to central nervous system germ cell tumors
Presenter: Guangyu Wang
Session: Poster session 09
513P - Cyclin pathway in oligodendrogliomas IDH mut and 1p/19q codeleted
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 09